AMRN—When I looked into Lovaza patent portfolio on the FDA OB site, Lovaza has only 3 patents listed whereas Vascepa has 8 currently listed and counting related to the Anchor trial.
What matters is not the quantity of patents in the Orange Book, but rather the quality. AMRN’s patents will (IMO) be challenged on the basis of obviousness.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.